Rabbit anti-rabies immunoglobulins production and evaluation.

The research paper revolves around the production and evaluation of rabbit anti-rabies immunoglobulins and their possible usage as a substitute for human and horse rabies immunoglobulin, showing that the rabbit version is safe and potentially more effective.

Objective of the Research

• The study is conducted due to the shortcomings of human and equine (horse) rabies immunoglobulin.
• The objective is to develop a suitable substitute for these types of rabies immunoglobulin, particularly for populations in developing countries.
• The substitute is aimed at improving safety and efficacy in the post-exposure prophylaxis of rabies, a potentially lethal disease.

Process of the Research

• In this research, rabbits are used as bioreactors to produce anti-rabies immunoglobulins which are specific to the rabies virus.
• The generated rabbit anti-rabies immunoglobulins (RRIG) are then put through various tests for characterization, including ELISA (enzyme-linked immunosorbent assay), affinity assay, IFA (immunofluorescence assay), immunocytochemistry, and RFFIT (rapid fluorescent focus inhibition test).

Findings from the Research

• ELISA, affinity assay and IFA tests reveal that RRIG binds specifically to rabies virions – virus particles capable of infecting host cells.
• The RFFIT test demonstrated that the RRIG has neutralizing activity against the rabies virus.
• An in vivo test in a Kunming mouse model further confirmed the safety and efficacy of RRIG. When mice were exposed to a lethal dose of the rabies virus (RV), the protection rate offered by RRIG treatment was found to be 25% higher than that provided by human rabies immunoglobulin (HRIG).

Conclusions from the Research

• The study’s results suggest that RRIG is a promising candidate to replace current rabies immunoglobulin in post-exposure prophylaxis.
• This could have significant implications for the treatment of rabies, particularly in developing countries where access to or trust in human and horse rabies immunoglobulins may be limited.